Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.71 |
| ▸ | NPC1 | O15118 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.69 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | MAOB | P27338 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517932 | 1.00 | FPR2 (0.74) | FPR2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL9637653 | 0.88 | MEN1 (0.77) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL30051982 | 0.88 | MEN1 (0.77) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL10665495 | 0.86 | RAB9A (0.79) | RAB9ANPC1MEN1KMT2AKDM4E | |
| Bromide SCHEMBL29417998 | 0.86 | MEN1 (0.74) | RAB9ANPC1MEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL29388210 | 0.86 | MEN1 (0.74) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL9190799 | 0.84 | TAAR1 (0.68) | FPR2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL7849600 | 0.83 | RAB9A (0.71) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL19932355 | 0.83 | RAB9A (0.71) | RAB9ANPC1MEN1KMT2AKDM4E | |
| SCHEMBL5853939 | 0.83 | RAB9A (1.00) | RAB9ANPC1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| CN-110437140-A | It is a kind of inhibit SREBP-1 target spot compound and its application | CHINESE PLA GENERAL HOSPITAL | 2019-11-12 | — | — | CN | claimed |
| CN-114025763-B | Adenosine compound, pharmaceutically acceptable salt or stereoisomer thereof and application | 中国人民解放军军事科学院军事医学研究院 | 2023-09-12 | — | — | CN | disclosed |
| US-20220332750-A1 | ADENOSINE COMPOUND, ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ITS STEREOISOMER AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3988100-A1 | ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF, AND USE | Academy Of Military Medical Sciences (CN) | 2022-04-27 | — | — | EP | disclosed |
| CN-114025763-A | Adenosine compound, pharmaceutically acceptable salt or stereoisomer thereof and application | 中国人民解放军军事科学院军事医学研究院 | 2022-02-08 | — | — | CN | disclosed |
| CN-110437140-B | Compound for inhibiting SREBP-1 target and application thereof | 中国人民解放军总医院 | 2021-08-03 | — | — | CN | disclosed |
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | THE NATIONAL INSTITUTE OF PARASITIC DISEASES, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION (CN) | 2021-01-28 | — | — | US | disclosed |
| CN-110437140-A | It is a kind of inhibit SREBP-1 target spot compound and its application | CHINESE PLA GENERAL HOSPITAL | 2019-11-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022340-A1 | USE OF PYRIDINE UREA COMPOUND HAVING SNAIL-KILLING ACTIVITY | SLC14A1, UACA, UROD | FPR2 3331/4885RAB9A 1093/4885NPC1 1905/4885 |
| US-20220332750-A1 | ADENOSINE COMPOUND, ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ITS STEREOISOMER AND USE THEREOF | ADORA2A, ADORA3, ADORA1 | FPR2 1505/4885RAB9A 1381/4885NPC1 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.